PHILADELPHIA, Oct. 29, 2025 -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws.
Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Radha Raghavan at rraghavan@bergermontague.com or (215) 875-4698, or CLICK HERE.
Headquartered in San Francisco, Akero is a clinical stage biopharmaceutical company whose lead product candidate is efruxifermin (EFX), a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Berger Montague's investigation centers on a proposed merger with Novo Nordisk A/S, announced on October 9, 2025, whereby Akero shareholders will receive $54.00 per share in cash and one Contingent Value Right entitling each holder to receive $6.00 per share if Akero's lead product candidate efruxifermin, a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), achieves regulatory approval by June 30, 2031.
About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Radha Raghavan
Berger Montague
(215) 875-4698
rraghavan@bergermontague.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
